Product
Lymphodepletion with cyclophosphamide
1 clinical trial
2 indications
Indication
Acute Lymphoblastic LeukemiaIndication
Burkitt lymphomaClinical trial
Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2028-12-31